Plasma Proneurotensin as a Predictive Biomarker for Breast Cancer in Genetically Predisposed Patients

Overview

About this study

The purpose of this study is to assess whether elevated fasting plasma proneurotensin levels are common in patients genetically predisposed to breast cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Any breast cancer-specific genetic mutation-positive (by genetic testing) patient with or without in situ or invasive breast cancer, with or without having had surgical treatment (i.e., mastectomy).

Exclusion Criteria: 

  • Children (<18 years of age). 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Leslie Donato, Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Toshi Ghosh M.D.

Ghosh.Toshi@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Leslie Donato, Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Stephanie Hafner B.S.

(507) 293-0241

Hafner.Stephanie@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20391803

Mayo Clinic Footer